279 related articles for article (PubMed ID: 15720184)
1. MDM2 is a central node in the p53 pathway: 12 years and counting.
Bond GL; Hu W; Levine AJ
Curr Cancer Drug Targets; 2005 Feb; 5(1):3-8. PubMed ID: 15720184
[TBL] [Abstract][Full Text] [Related]
2. p53-independent activities of MDM2 and their relevance to cancer therapy.
Zhang Z; Zhang R
Curr Cancer Drug Targets; 2005 Feb; 5(1):9-20. PubMed ID: 15720185
[TBL] [Abstract][Full Text] [Related]
3. Targeting p53-MDM2-MDMX loop for cancer therapy.
Zhang Q; Zeng SX; Lu H
Subcell Biochem; 2014; 85():281-319. PubMed ID: 25201201
[TBL] [Abstract][Full Text] [Related]
4. Mdmx as an essential regulator of p53 activity.
Marine JC; Jochemsen AG
Biochem Biophys Res Commun; 2005 Jun; 331(3):750-60. PubMed ID: 15865931
[TBL] [Abstract][Full Text] [Related]
5. Genotoxic stress induces coordinately regulated alternative splicing of the p53 modulators MDM2 and MDM4.
Chandler DS; Singh RK; Caldwell LC; Bitler JL; Lozano G
Cancer Res; 2006 Oct; 66(19):9502-8. PubMed ID: 17018606
[TBL] [Abstract][Full Text] [Related]
6. Dysfunction of p53 pathway in human colorectal cancer: analysis of p53 gene mutation and the expression of the p53-associated factors p14ARF, p33ING1, p21WAF1 and MDM2.
Tachibana M; Kawamata H; Fujimori T; Omotehara F; Horiuchi H; Ohkura Y; Igarashi S; Kotake K; Kubota K
Int J Oncol; 2004 Oct; 25(4):913-20. PubMed ID: 15375540
[TBL] [Abstract][Full Text] [Related]
7. MDM2, an introduction.
Iwakuma T; Lozano G
Mol Cancer Res; 2003 Dec; 1(14):993-1000. PubMed ID: 14707282
[TBL] [Abstract][Full Text] [Related]
8. [Mdm2, p53 and the cell cycle: when well enough is best left alone].
Maréchal V
Pathol Biol (Paris); 1997 Dec; 45(10):824-32. PubMed ID: 9769946
[TBL] [Abstract][Full Text] [Related]
9. Mdm2 and MdmX involvement in human cancer.
Berberich SJ
Subcell Biochem; 2014; 85():263-80. PubMed ID: 25201200
[TBL] [Abstract][Full Text] [Related]
10. Bypass of abnormal MDM2 inhibition of p53-dependent growth suppression.
Meng RD; Shih H; Prabhu NS; George DL; el-Deiry WS
Clin Cancer Res; 1998 Jan; 4(1):251-9. PubMed ID: 9516979
[TBL] [Abstract][Full Text] [Related]
11. Rescue of Mdm4-deficient mice by Mdm2 reveals functional overlap of Mdm2 and Mdm4 in development.
Steinman HA; Hoover KM; Keeler ML; Sands AT; Jones SN
Oncogene; 2005 Nov; 24(53):7935-40. PubMed ID: 16027727
[TBL] [Abstract][Full Text] [Related]
12. MDM2 oncogene as a novel target for human cancer therapy.
Zhang ; Wang H
Curr Pharm Des; 2000 Mar; 6(4):393-416. PubMed ID: 10788589
[TBL] [Abstract][Full Text] [Related]
13. C-Abl as a modulator of p53.
Levav-Cohen Y; Goldberg Z; Zuckerman V; Grossman T; Haupt S; Haupt Y
Biochem Biophys Res Commun; 2005 Jun; 331(3):737-49. PubMed ID: 15865930
[TBL] [Abstract][Full Text] [Related]
14. Ubiquitous induction of p53 in tumor cells by antisense inhibition of MDM2 expression.
Chen L; Lu W; Agrawal S; Zhou W; Zhang R; Chen J
Mol Med; 1999 Jan; 5(1):21-34. PubMed ID: 10072445
[TBL] [Abstract][Full Text] [Related]
15. A high-frequency regulatory polymorphism in the p53 pathway accelerates tumor development.
Post SM; Quintás-Cardama A; Pant V; Iwakuma T; Hamir A; Jackson JG; Maccio DR; Bond GL; Johnson DG; Levine AJ; Lozano G
Cancer Cell; 2010 Sep; 18(3):220-30. PubMed ID: 20832750
[TBL] [Abstract][Full Text] [Related]
16. Regulation of mdm2 expression by p53: alternative promoters produce transcripts with nonidentical translation potential.
Barak Y; Gottlieb E; Juven-Gershon T; Oren M
Genes Dev; 1994 Aug; 8(15):1739-49. PubMed ID: 7958853
[TBL] [Abstract][Full Text] [Related]
17. [Study of the molecular mechanisms controlling activity of protein p53 in the development of new strategies in cancer therapeutics].
Marine Ch
Bull Mem Acad R Med Belg; 2009; 164(5-6):175-80; discussion 180-1. PubMed ID: 20666148
[TBL] [Abstract][Full Text] [Related]
18. MDM2--master regulator of the p53 tumor suppressor protein.
Momand J; Wu HH; Dasgupta G
Gene; 2000 Jan; 242(1-2):15-29. PubMed ID: 10721693
[TBL] [Abstract][Full Text] [Related]
19. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans.
Bond GL; Hu W; Bond EE; Robins H; Lutzker SG; Arva NC; Bargonetti J; Bartel F; Taubert H; Wuerl P; Onel K; Yip L; Hwang SJ; Strong LC; Lozano G; Levine AJ
Cell; 2004 Nov; 119(5):591-602. PubMed ID: 15550242
[TBL] [Abstract][Full Text] [Related]
20. The p53 and Mdm2 families in cancer.
Michael D; Oren M
Curr Opin Genet Dev; 2002 Feb; 12(1):53-9. PubMed ID: 11790555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
